MARKET

NBRV

NBRV

Nabriva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.890
+0.060
+3.28%
Opening 15:08 11/21 EST
OPEN
1.850
PREV CLOSE
1.830
HIGH
1.890
LOW
1.830
VOLUME
564.83K
TURNOVER
--
52 WEEK HIGH
3.270
52 WEEK LOW
1.120
MARKET CAP
148.08M
P/E (TTM)
-1.2383
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NBRV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NBRV News

  • Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio
  • Benzinga.19h ago
  • Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio
  • Benzinga.19h ago
  • Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship
  • GlobeNewswire.3d ago
  • YY, CLVS among premarket gainers
  • Seeking Alpha - Article.11/13 14:10

More

Industry

Biotechnology & Medical Research
-0.41%
Pharmaceuticals & Medical Research
+0.29%

Hot Stocks

Name
Price
%Change

About NBRV

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
More

Webull offers Nabriva Therapeutics PLC - ADR (NBRV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.